Clinical Chemistry
Clinical Chemistry develops and supports unique and innovative laboratory solutions for clinical chemistry and toxicology. Our instruments and reagents help clinicians worldwide to diagnose conditions such as diabetes, and to identify drug abuse.
Strengthening partnerships and market leader positioning
In 2023 we won a tender with IMSS, Mexico’s largest healthcare institution, increasing our installed base at its hospitals by 62%. In addition, we also strengthened our position as the leader in the toxicology market in Italy, making 2023 a very successful year.
Other Specialized Diagnostics products
Continued growth in 2023
In addition to our portfolio of proprietary Specialized Diagnostic products, some of our affiliates, mainly those in Spain, Portugal, and Mexico, distribute analyzers, reagents, and controls from internationally recognized partners.
We are proud of these long-standing partnerships, which allow us to deliver these products essential to molecular biology, microbiology, and applied science. This segment of our business continues to grow thanks to the specialized, technical, and application expertise within our affiliates.
Medical Devices and
Scientific Instrumentation distribution
In 2023, all three companies specializing in the distribution of medical devices and scientific instrumentation distribution achieved significant milestones, including new distribution agreements with various partners. This is vital for the future growth and sustainability of the businesses.
Izasa Medical
Izasa Medical had an exceptional year across all business units, in particular the cardiovascular business, which grew by over 25% compared to 2022. Additionally, the company launched numerous products and signed up multiple new partnerships in areas such as wound care and surgical oncology.
Izasa Scientific
Izasa Scientific achieved a remarkable 9% growth in sales, boosted by the extraordinary performance of its business in Portugal and its sales of equipment for industry, which grew 38% vs 2022. Several new partnerships were signed, strengthening its portfolio in fields like advanced therapies and nanotechnologies, which are expected to be two of the key growth drivers in the coming years.
MC Medical
MC Medical consolidated its renewed structure, exceeding its operating profit budget and signed a distribution agreement with Siemens Healthineers for the commercialization of its ultrasound equipment in Portugal.
Infusion Therapy
Dosi-Fuser®, a Leventon product, was reintroduced to the US market after a 5-year absence, and already signed up its first customers. In Europe, Dosi-Fuser resumed sales after obtaining the new MDR certification. Leventon is also launching several initiatives and projects to enhance the competitiveness of its products and increase penetration in new markets.